These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16973798)

  • 1. Iron chelating in thalassaemia with left ventricular dysfunction.
    Cagirci G; Tufekcioglu O; Yetim M
    Heart; 2006 Oct; 92(10):1440. PubMed ID: 16973798
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalassaemia major: the murky story of deferiprone.
    Savulescu J
    BMJ; 2004 Feb; 328(7436):358-9. PubMed ID: 14962851
    [No Abstract]   [Full Text] [Related]  

  • 3. [Iron chelators].
    Villegas A
    Med Clin (Barc); 1994 May; 102(19):739-41. PubMed ID: 8041203
    [No Abstract]   [Full Text] [Related]  

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R; Engelhardt R
    Lancet; 2003 Jan; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox Novartis.
    Barton JC
    Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of cardiac function in a successful full-term pregnancy in a homozygous beta-thalassemia major: does chelation have a positive role?
    Tsironi M; Ladis V; Margellis Z; Deftereos S; Kattamis Ch; Aessopos A
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):117-8. PubMed ID: 15866098
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major.
    Christoforidis A; Perifanis V; Athanassiou-Metaxa M
    Br J Haematol; 2006 Oct; 135(2):271-2. PubMed ID: 16965387
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucose tolerance and beta-cell secretion in patients with thalassaemia major.
    Mangiagli A; Italia S; Campisi S
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():985-6. PubMed ID: 10091179
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical resection of multiple right atrial masses in a child with beta thalassaemia and receiving desferioxamine.
    West M; Malik GA; Pollock JC
    Heart; 2003 May; 89(5):501. PubMed ID: 12695451
    [No Abstract]   [Full Text] [Related]  

  • 11. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia.
    Aessopos A; Kati M; Tsironi M; Polonifi E; Farmakis D
    Haematologica; 2006 May; 91(5 Suppl):ECR11. PubMed ID: 16709519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactory Dysfunction in β Thalassemia Major Patients Treated With Iron-Chelating Agents.
    Derin S; Erdogan S; Sahan M; Azik MF; Derin H; Topal Y; Topal H
    Ear Nose Throat J; 2019 Sep; 98(8):NP125-NP130. PubMed ID: 31142160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum superoxide dismutase levels of beta thalassemia patients and effects of high dosage of intravenous desferrioxamine treatment on superoxide dismutase levels.
    Tekin M; Akar N; Eğin Y; Cin S
    Pediatr Hematol Oncol; 1998; 15(4):371-4. PubMed ID: 9658440
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocrine complications in thalassaemia major.
    De Sanctis V; Vullo C; Katz M; Wonke B; Hoffbrand VA; Di Palma A; Bagni B
    Prog Clin Biol Res; 1989; 309():77-83. PubMed ID: 2780752
    [No Abstract]   [Full Text] [Related]  

  • 15. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload and antioxidant status in patients with beta-thalassemia major.
    Reller K; Dresow B; Collell M; Fischer R; Engelhardt R; Nielsen P; Dürken M; Politis C; Piga A
    Ann N Y Acad Sci; 1998 Jun; 850():463-5. PubMed ID: 9668585
    [No Abstract]   [Full Text] [Related]  

  • 17. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.
    Modell B; Khan M; Darlison M
    Lancet; 2000 Jun; 355(9220):2051-2. PubMed ID: 10885361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of echocardiography parameters with cardiac magnetic resonance imaging in transfusion-dependent thalassaemia major.
    Aessopos A; Giakoumis A; Fragodimitri C; Karabatsos F; Hatziliami A; Yousef J; Gotsis E; Berdoukas V; Karagiorga M
    Eur J Haematol; 2007 Jan; 78(1):58-65. PubMed ID: 17038018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy Outcome among Women with Beta-Thalassemia Major in North Sardinia.
    Fozza C; Asara MA; Vacca N; Caggiari S; Monti A; Zaccheddu F; Capobianco G; Dessole S; Dore F; Antonucci R
    Acta Haematol; 2017; 138(3):166-167. PubMed ID: 28992618
    [No Abstract]   [Full Text] [Related]  

  • 20. Compliance with iron chelation therapy in beta thalassaemia.
    Vidler V
    Paediatr Nurs; 1998 Oct; 10(8):17-8, 20. PubMed ID: 10095669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.